Adaptimmune Therapeutics (ADAP) Prices 11.25M IPO at $17/ADS

Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced the pricing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,687,500 ADSs. The ADSs are expected to begin trading on the NASDAQ Global Select Market under the symbol "ADAP" on May 6, 2015. The offering is expected to close on May 11, 2015, subject to customary closing conditions. Adaptimmune estimates net proceeds from the offering will be approximately $175.7 million.

BofA Merrill Lynch, Cowen and Company and Leerink Partners LLC are acting as joint book-running managers and Guggenheim Securities is acting as lead manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (SEC) on May 5, 2015.

You May Also Be Interested In

• VICI Properties closes $1.75B senior unsecured notes offering
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027
• Silence Therapeutics closes $201M public offering of ADSs